Chronix notes abstract disclosure for forthcoming ASCO presentation. Head and neck cancer study finds CNI score to be a stronger predictor of time to recurrence than current method based on lymph node invasion.

The poster presentation is entitled Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer.

It presents data from a study that examined copy number instability (CNI) in circulating tumour DNA from 54 patients undergoing surgery for head and neck cancer and compared the Chronix CNI-based test as a predictor of time to progression with the current method based on the degree of tumour invasion of lymph nodes (pN status).

By | May 18th, 2017|Chronix news|0 Comments

Chronix Biomedical is pleased to announce that results of a clinical trial of its liquid biopsy test have been accepted for presentation at the ASCO Annual Meeting.

Chronix Biomedical

The poster presentation will cover results of a study evaluating the Copy Number Instability (CNI) score as a prognostic test in head and neck cancer.

By | April 24th, 2017|Chronix news|0 Comments

Chronix Biomedical Study Demonstrates Its Blood Test Can Predict Response to Cancer Immunotherapy

Chronix Biomedical

First study of a liquid biopsy to predict response to immunotherapy...

By | March 20th, 2017|Chronix news|0 Comments

Chronix Biomedical provides update on studies and presentations

Chronix Biomedical

Data from pilot studies using Chronix’s CNI test submitted for presentation at a high profile scientific meeting...

By | February 27th, 2017|Chronix news|0 Comments

10 Cancer Symptoms

Chronix Biomedical

The best way to fight cancer is to diagnose it in its early stage...

By | February 6th, 2017|Chronix news|0 Comments


Chronix Biomedical

World Cancer Day is a perfect opportunity to focus on your health state...

By | February 3rd, 2017|Chronix news|0 Comments

Blood test could identify aggressive prostate cancer

The Times

The Times: thousands of men with prostate cancer could be saved from unnecessary operations thanks to a blood test...

By | November 8th, 2016|Chronix news|0 Comments

Chronix Biomedical updates on progress with prostate and pancreatic cancer validation studies

Chronix Biomedical

Chronix Biomedical, Inc., a developer of novel cancer blood-based molecular diagnostics, is pleased to update investors on the progress of two clinical studies...

By | November 3rd, 2016|Chronix news|0 Comments

Cancer – what you need to know?

UK Cancer Research

UK Cancer Research has created Cancer Statistic: Early diagnosis of cancer increases the chances of a full recovery. That's why Advanced Cancer Diagnostics puts attention to the importance of cancer screening. Cancer can’t...

By | October 28th, 2016|Chronix news|0 Comments

Cancer Moonshot – Initiative of the Government of the United States

Chronix Biomedical

"The Cancer Moonshot Initiative’s mission of speeding cures for the hundreds of cancers we treat is much more complex than putting a man on the moon." President Barack Obama’s announcement of a Cancer Moonshot Initiative...

By | October 13th, 2016|Chronix news|0 Comments